Rafferty Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Rafferty Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,136,381	Closed	-$4.77M	–	1172
2023 Q1	$4.77M	Sell	1,136,381 -334,976	-23%	-$1.74M	0.03%	394
2022 Q4	$8.84M	Buy	1,471,357 +378,314	+35%	+$2.06M	0.07%	218
2022 Q3	$6.36M	Buy	1,093,043 +655,442	+150%	+$4.08M	0.07%	267
2022 Q2	$2.61M	Buy	+437,601	New	+$2.24M	0.02%	413

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Rafferty Asset Management's CTIC Position: Q2 2023 in Review

Rafferty Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,136,381 shares — an estimated $4.77M sold.

Rafferty Asset Management first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $8.84M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Rafferty Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 1,136,381 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.77M.
Rafferty Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Rafferty Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.84M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.